Amdocs says short report ‘contains misleading claims, baseless speculation’

Contacted by The Fly after Jehoshaphat Research published a report alleging a “massive financial deception” taking place at Amdocs, a spokesperson for the company said that, “Amdocs delivered record revenue of more than $4.2B for the full fiscal year 2020, with stable non-GAAP operating margins. Our financial outlook remains positive and we will communicate directly with our investors and customers regarding this short seller’s report. The report contains misleading claims, inaccurate statements and baseless speculation that appears designed to manipulate the stock price to serve the short seller’s interests ahead of those of Amdocs’ shareholders.” Jehoshaphat had cited in its report “extensive evidence” from the national corporate registry filings of dozens of subsidiaries from around the globe, which was compared to the company’s public filings and showed “wildly overstated profit margins, a balance sheet that is far from the cash-rich fortress it appears to be, and a revolving door of company auditors resigning from their posts in multiple countries.” In late morning trading, shares of Amdocs have dropped over 7% to $73.60.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire